Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Benign breast disease affects almost all women, although only one out of 11 will eventually develop breast cancer. Fibrocystic disease or benign breast mastopathies have been associated with an increased propensity to progress to malignancy. However, the increased relative risk for women with benign breast disease developing breast cancer appears to be associated with proliferative benign disease in association with atypia. Their cumulative risk may be as high as 30%. These women represent 3-5% of women with benign disease. They clearly warrant more careful screening and follow-up. The etiology of benign breast mastopathies is unknown, but its incidence and relationship to hormonal events suggests that many of the histologic entities represent an endocrine response. Many hormonal manipulations have been shown to decrease mastodynia and reduce the incidence of breast aspirations and biopsies. However, these and other therapeutic interventions have not been shown to reduce the incidence of breast cancer in women who are at high risk.
 ...
PMID:Breast diseases and the internist. 329 52

The importance of breast pain as a presenting symptom of breast cancer was assessed in 200 women with localized mastalgia but negative physical examination and in 478 women with operable breast cancer. In the first group, mammography detected five cases of subclinical breast cancer at the site of pain. In the second group, 86 patients (18%) reported localized pain as presenting symptom, followed, at different intervals, by the detection of a breast lump. Localized pain can be considered a presenting symptom of breast cancer thus requiring a careful physical and mammographic examination, especially when risk factors are associated.
 ...
PMID:Localized mastalgia as presenting symptom in breast cancer. 337 73

For investigation of the bioactivity of circulating prolactin and growth hormone (lactogenic hormones) in symptomatic benign breast disease, serum was assayed by the Nb2 lymphoma cell method in premenopausal patients with cystic breast disease and cyclic mastalgia and in normal premenopausal women. The results were compared with serum prolactin and growth hormone concentrations determined by radioimmunoassay. The serum bioassayable hormone levels in the benign breast disease patients (74.0 +/- 77.6 ng/ml) were significantly higher (P less than .001) than in normal women (23.8 +/- 10.7 ng/ml). There were no significant differences in the radioimmunoassayable prolactin or growth hormone levels between the 2 groups. When 16 cystic breast disease patients were placed on a low-fat (20% of total kilocalories) diet for 3 months, there were significant reductions in the serum bioassayable hormone levels (P less than .02). It is concluded that the bioactivity of prolactin may be elevated in the serum of patients with cystic breast disease and cyclic mastalgia, without corresponding increases in levels determined by radioimmunoassay; that this abnormality is reversible by a reduction in dietary fat consumption to 20% of the total kilocalories; and that serum prolactin may provide a valuable biomarker in clinical trials of a low-fat diet in women at high breast cancer risk.
 ...
PMID:Effect of a low-fat diet on hormone levels in women with cystic breast disease. II. Serum radioimmunoassayable prolactin and growth hormone and bioactive lactogenic hormones. 347 May 39

In a prospective longitudinal study over several years, 58 patients with breast cancer are compared to 52 patients with fibrocystic disease and 24 patients with mastodynia. Results of coping (as assessed with the Bernese Coping Modes) are presented for the illness course of the first 6 months: (1) There is considerable variation of coping depending on illness situation and illness state. A core group of coping modes is predominant in most situations: 'attention & care', 'problem analysis', and 'Tackling'. In average 10 different coping modes were used by patients per given illness situation. (2) The different aspects of illness (in the same organ) ask for different coping. In the initial evaluation phase, however, the possibly fatal diagnosis overrides these differences. (3) Change over time (first 6 months) is net. Besides the core group of coping modes mentioned above, there is more variability in coping; in cancer a trend from a more fighting to a more accepting attitude is obvious; in fibrocystic disease more restricted coping is observed. Interdependence of coping with emotional stability and social adaptation will be studied as well.
 ...
PMID:Coping with breast cancer--a longitudinal prospective study. 350 16

The incidence of cyclical mastalgia in well women presenting for breast screening was 69 per cent. The incidence of cyclical mastalgia increases with age up to the menopause. There was a higher incidence of 'high risk' mammographic patterns and a lower incidence of 'low risk' patterns, according to the Wolfe classification, in women with cyclical mastalgia compared with the rest of the screened population. This finding correlated with the severity, duration and need for treatment. The differences in breast pattern did not persist after the menopause. The question of whether or not cyclical mastalgia can be regarded as a risk factor for breast cancer is uncertain and needs further evaluation.
 ...
PMID:Cyclical mastalgia: clinical and mammographic observations in a screened population. 356 18

The present investigation was undertaken to study the laterality of breast tumors on the basis of the Estonian Cancer Registry data for the period of 1968-1981 and special breast screening data for 1974-1983. The ratio of the patients with the left- and right-sided disease was 1.12 (p less than 0.001) for breast cancer, 1.75 (p less than 0.001)--for fibroadenomatosis of the mammary gland, and 1.43 (p less than 0.001)--for mastodynia. Left-sided carcinoma was more common in patients with left nipple discharge which was accompanied by "early menarche" more often than discharge from the right nipple (p less than 0.05). There was no significant difference in the patients' survival versus the laterality of breast cancer.
 ...
PMID:[Prevalence of tumors in the left breast]. 359 Jun 67

We are conducting a study to determine whether risk factors associated with specific pathologic subtypes of benign breast disease (BBD) are similar to those for breast cancer and to evaluate the relationship between clinical and mammographic features of BBD. All women participating in the Canadian National Study of Breast Cancer Screening in Vancouver, B.C., Canada (expected 10,000) are invited to complete a questionnaire designed to gather clinical and epidemiologic information on BBD. Preliminary analysis of the first 736 participants indicates that breast pain and/or tenderness is a significant problem which in its severe from is distressing, anxiety provoking, and adversely affecting quality of life. Breast pain and tenderness is also associated with an increased frequency of clinical signs of BBD and of dense mammographic patterns.
 ...
PMID:Study of benign breast disease in a population screened for breast cancer. 373 Nov 90

Conservative management of breast masses in adolescents is generally advocated in consideration of the low incidence of breast cancer. A retrospective chart review of 130 female patients seen in a general adolescent clinic over a two-year period was performed. The mean age was 17.5 years (range 12-21). One hundred and seven (88% of available data) had self-discovered lesions. Fibrocystic disease was clinically diagnosed in 66 (51%) patients, while 19 (15%) had fibroadenomas and 17 (13%) had a normal breast examination. Of the remaining patients, six (5%) had mastalgia, five (4%) had mastitis/abscess, three (2%) has asymmetry, three (2%) had hypertrophy, two (1%) had breast changes of early pregnancy, two (1%) had hematoma, one (1%) had axillary lymphadenopathy, and six (5%) had unknown. Excisional biopsy was performed on eleven patients; it revealed fibroadenoma in eight, and one each had a hematoma, granular cell myoblastoma, and breast abscess. Improvement or complete resolution of breast masses was documented in 31 (47%) of the patients with fibrocystic disease.
 ...
PMID:Breast masses in adolescent females. 404 71

Severe breast pain or mastalgia is a common symptom, affecting up to 70% of the female population at some time in their lives. It accounts for approximately 50% of referrals to a specialised breast clinic, two-thirds of patients having cyclical and one-third experiencing noncyclical mastalgia, or pain arising from the chest wall deep to the breast. After exclusion of breast cancer and proper reassurance, 85% of patients can be discharged from the clinic without specific treatment. In only 15% of patients is the pain severe enough to affect their lifestyle and warrant drug therapy. Using EF-12 (gammalinolenic acid; gamolenic acid) as first-line therapy, with danazol and bromocriptine usually as second-line agents, a clinically useful improvement in pain can be anticipated in 92% of patients with cyclical and 64% with noncyclical mastalgia. Patients with severe recurrent or refractory mastalgia may require treatment with tamoxifen, goserelin or testosterone, but the short and long term adverse effects of these drugs preclude their use as first-line agents. Chest wall pain is usually self-limiting, but symptomatic relief can often be obtained using steroidal and local anaesthetic injections or nonsteroidal anti-inflammatory drugs.
 ...
PMID:Drug therapy of mastalgia. What are the options? 753 Jun 28

Most women have fibrocystic changes in their breasts. Patients with proliferative changes with atypia are at an increased risk of breast cancer. The management of mastalgia is the challenge most frequently encountered in patients with fibrocystic changes. Clinically, the types and variants of fibrocystic changes are sometimes difficult to distinguish. When the diagnosis of fibrocystic changes is unclear, a histologic evaluation biopsy, open surgical biopsy, should be performed.
 ...
PMID:Fibrocystic changes. 781 5


<< Previous 1 2 3 4 5 6 7 Next >>